Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
about
Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis.Nationwide Surveillance of Novel Oxazolidinone Resistance Gene optrA in Enterococcus Isolates in China from 2004 to 2014.Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infectionsIn Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977).In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries.Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015).Long-lasting successful dissemination of resistance to oxazolidinones in MDR Staphylococcus epidermidis clinical isolates in a tertiary care hospital in France.Retrospective analysis of genome sequences revealed the wide dissemination of optrA in Gram-positive bacteria.Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic.Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant EnterococcusApplication of gene sequence analysis for the identification of species of coagulase-negative staphylococci in clinical samples and evaluation of their antimicrobial resistance pattern
P2860
Q37119083-56C96138-8867-463F-9A4D-A0E670E4C1A7Q37428734-8B1BE713-04CE-4449-86A8-9F74D38D55A2Q38929509-E436D7C4-7609-4708-97CF-B3A236094A6DQ39016281-5A01CB61-1259-43C2-817B-8ECA8C9BB77CQ39067666-D6662E1A-07FC-45D3-81C3-BE34AC4D77ECQ40287328-3E648077-801D-4BE1-A603-529093896211Q42680740-4916D7A4-41AD-4D4C-AAB0-BC1B381B4066Q46298851-DAE9CF24-F78F-4F39-AAEE-C45BB56A3F80Q47141945-EE8A4DA4-4900-4B37-B8C4-E5C2950DFEE2Q47577709-F9506B2E-F064-4462-A651-5FDEF3F0D941Q54266471-296B1F2B-FE05-4636-A54D-734935DC703EQ55250490-DFF117A3-95CD-45D2-AE7D-5A2D4EC3EF9DQ57480754-5A825244-6AFF-438F-95A2-790605A0C0AAQ58719906-99AF0900-4A0D-4E81-B15F-A1811FF7D1CF
P2860
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
@ast
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
@en
type
label
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
@ast
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
@en
prefLabel
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
@ast
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
@en
P2093
P2860
P356
P1476
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).
@en
P2093
James E Ross
Jennifer M Streit
Patricia A Hogan
Rodrigo E Mendes
Ronald N Jones
P2860
P304
P356
10.1128/AAC.02803-15
P407
P577
2016-02-01T00:00:00Z